The Relationship between Anti-Factor Xa Level and Clinical Outcome in Patients Receiving Enoxaparine Low Molecular Weight Heparin to Prevent Deep Vein Thrombosis after Hip Replacement

Summary

Studies in experimental animals have demonstrated that there is a relationship between levels of low molecular weight (LMW) heparin and both bleeding and inhibition of thrombosis. The relationship between these outcomes and ex vivo anti-factor Xa levels has been examined in 163 patients undergoing total hip replacement who were given prophylaxis once daily with a LMW heparin (enoxaparine). Fifty patients received 60 mg of enoxaparine and 113 received 40 mg, both regimens being administered subcutaneously once daily. Blood samples for anti-factor Xa levels were collected 12 hours after the injection on the day of surgery and on days 1, 3 and 6, postoperatively. The incidence of wound hematoma was 5.3% when the maximum anti-factor Xa level was ≤0.2 units per ml, but increased to 24.5% when the anti-factor Xa level exceeded 0.2 units per ml, P = 0.0008. The incidence of postoperative thrombosis was low (6.3%) if the minimum anti-factor Xa level exceeded 0.1 units per ml, but increased to 14.6% when ≤0.1 units per ml, and to 18.8% if the anti-factor Xa level was ≤0.05 units per ml. Regression analysis revealed that there was a statistically significant relationship between anti-factor Xa level and wound hematoma, P = 0.002 and anti-factor Xa level and thrombosis, P = 0.03. These findings suggest that when enoxaparine is administered as a once daily subcutaneous injection, the 12 hour anti-factor Xa level should not exceed 0.2 units per ml to minimize bleeding and levels >0.05 units per ml should be obtained to optimize efficacy.

Keywords

Low molecular weight heparin - Hip replacement - Deep vein thrombosis

• References

• 1 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 2 Ockelford PA, Carter CJ, Cerskus A, Smith CA, Hirsh J. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin III affinity heparin fraction. Thromb Res 1982; 27: 679-690
• 3 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-X_a activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
• 4 Fernandez FA, N'guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet effect. Thromb Res 1986; 43: 491-495
• 5 Hirsh J, Ofosu FA, Levine M. The development of low molecular weight heparins for clinical use. In: Thrombosis and Haemostasis 1987. Verstraete M, Vermylen J, Lijnen R, Amout J. (eds). Leuven University Press; Leuven: 1987. pp 325-348
• 6 Levine MN, Hirsh J. Clinical use of low molecular weight heparins and heparinoids. Semin Thromb Haemostas 1988; 14: 116-125
• 7 ten Cate H, Henny CH P, ten Cate JW, Btiller HR, Dabhoiwala NF. Randomized double-blind, placebo controlled safety study of low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemostas 1987; 57: 92-96
• 8 Planes A, Vochelle N, Ferru J, Przyrowski D, Clerc J, Fagola M, Planes M. Enoxaparine low molecular weight heparin: its use in the prevention of deep venous thrombosis following total hip replacement. Haemostasis 1986; 16: 152-158
• 9 Planes A, Vochelle N, Mansat C. Prevention of deep vein thrombosis after total hip replacement by enoxaparine: one daily injection of 40 mg versus two daily injections of 20 mg. Thromb Haemostas 1987; 117 (Abstr 415).
• 10 Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemostas 1988; 60: 407-410
• 11 Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new low molecular weight heparin derivative: in vitro and in vivo studies. Thromb Res 1983; 31: 611-621
• 12 Colton T. Statistics in Medicine. Little; Brown, Boston: 1974. pp 127-146
• 13 Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. John Wiley; New York: 1981. pp 19-27
• 14 Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955; 11: 375-386
• 15 Cox DR. The analysis of binary data. Methuen; London: 1970. pp 14-26
• 16 Turpie AG G, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, Andrew M, Hull RD, Gent M. A randomized controlled trial of a low molecular weight heparin (enoxaparine) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1987; 315: 925-929
• 17 Samama M, Bernard P, Bonnardot VP, Tissot E, Lanson Y, Combe-Tamzali S. Low molecular weight heparin (enoxaparine) compared with unfractionated heparin thrice in day in prevention of postoperative thrombosis. Br J Surg 1988; 75: 128-131
• 18 Bergqvist D, Burmark US, Frisell J. et al. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily. A prospective double-blind multi-centre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
• 19 Roller M, Schoch U, Buchmann P, Largiader F, Von Felten A, Frick PG. Low molecular weight heparin (KABI-2165) as thromboprophylaxis in elective visceral surgery. A randomized double-blind study versus unfractionated heparin. Thromb Haemostas 1986; 56: 243-246
• 20 Caen JP. A randomized double-blind study between a low molecular weight heparin KABI 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. Thromb Haemostas 1988; 59: 216-220
• 21 Vitoux JF, Aiach M, Roncato M, Fiessinger JN. Should thrombo-prophylactic dosage of low molecular weight heparin be adapted to patient's weight?. Thromb Haemostas 1988; 59: 120